Researchers from Drexel University reversed symptoms of Alzheimer’s disease in fruit flies by restoring the balance between two epigenetic enzymes that regulate gene expression, a study shows.
Early in the progression of Alzheimer’s disease, cognitive impairment (such as difficulties with learning and memory) may be tied to the presence of elevated levels of the HDAC2 enzyme. HDAC2 helps control how genes linked to learning and memory are expressed. It appears that when HDAC2 overwhelms the enzyme it is paired with, which is called Tip60 HAT, it represses genes and leads to problems with neuroplasticity — the brain’s ability to adapt to new stimuli or recall reactions to stimuli it already encountered.
But a research team led by Priyalakshmi Panikker, a PhD student, and Felice Elefant, PhD, an associate professor, both in Drexel’s College of Arts and Sciences, performed tests in flies and found that if they added extra Tip60 HAT in the brain of flies that displayed symptoms close to Alzheimer’s disease, the balance between the enzymes could be successfully restored. When that balance came back, behaviors the team had taught the flies were able to be learned again and remembered.
“Our findings strongly support the concept of exploring the efficacy of specific Tip60 HAT activators, as well as identifying and manipulating additionally misregulated Tip60 target genes,” Elefant said.
Elefant, Panikker and their team — whose findings were published in the Journal of Neuroscience — looked at how Alzheimer’s disease affected flies early in their development, during their larval stages, to catch what might happen in Alzheimer’s well before the tell-tale symptoms arise.
“Many researchers that study Alzheimer’s disease utilize human post-mortem samples, and thus, they are not looking at what is happening during the early progression of neurodegeneration, including whether we can correctwhat is happening during these early stages ,” Elefant said.
For the study, flies were taught to associate a certain odor with sucrose — table sugar, which flies eat and is a positive reinforcement. After being exposed to the scent paired with sugar, the flies learned to move towards the scent even without the sugar present.
Flies that modeled Alzheimer’s disease showed no difference in their reaction to the smell they had earlier been condition to. This showed that their ability to learn and remember this association was negatively affected.
But once Tip60 HAT was introduced in the brain to correct the identified Tip60 HAT/HDAC2 imbalance, these flies showed a reaction time comparable to the ones without the Alzheimer’s type of condition. This indicated that they recovered their ability to learn and remember after the epigenetic balance was reintroduced.
Moreover, when researchers identified a collection of genes related to brain function that had been repressed in the flies — due to elevated HDAC2 — an introduction of increased Tip60 HAT levels in the brain restored regular function in 9 of the 11 genes tested.
The results Panikker and Elefant found were encouraging. More testing is needed, but Elefant’s goal is to find new avenues for gene therapy.
“When people age, they have a loss of memory but it’s not because there are mutations in their genes,” Elefant said. “It’s the way they’re packaged. They’re distorted. And we’re seeing non-invasive ways we might be able to prevent that early on.”
Those interested in reading the full study, “Restoring Tip60 HAT/HDAC2 balance in the neurodegenerative brain relieves epigenetic transcriptional repression and reinstates cognition,” can access it here.
The Latest on: Alzheimer’s disease
via Google News
The Latest on: Alzheimer’s disease
Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease
on May 23, 2018 at 6:53 am
TOKYO & DEERFIELD, Ill.--(BUSINESS WIRE)--May 23, 2018--Otsuka Pharmaceutical Company, Ltd. (Otsuka) and Lundbeck announce that the two companies’ third clinical Phase 3 study of brexpiprazole in the treatment of agitation in patients with dementia of ... […]
What really causes Alzheimer's and how might we fix it?
on May 23, 2018 at 6:13 am
There have been a lot of theories about what causes Alzheimer's disease. Many of them have given rise to experimental treatments of one form or another. None of them have worked much better than taking anything you might find in your spice rack. […]
Study predicts most people with earliest Alzheimer’s signs won’t develop dementia from the disease
on May 23, 2018 at 5:59 am
During the past decade, researchers have identified new ways to detect the earliest biological signs of Alzheimer’s disease. These early signs, which are detected by biomarkers, may be present before a person starts to exhibit physical symptoms. […]
Scot Brantley diagnosed with Alzheimer's disease
on May 22, 2018 at 5:56 pm
TAMPA, Fla -- Former Tampa Bay Buccaneers and Florida Gators linebacker Scot Brantley has been diagnosed with Alzheimer's disease. Brantley, known as a vicious hitters during his eight-season NFL stint in the 1980s, revealed on HBO's "Real Sports with ... […]
Most Preclinical AD Doesn't Progress to Dementia
on May 22, 2018 at 1:51 pm
Most people with preclinical Alzheimer's disease will not develop Alzheimer's dementia during their lifetimes, according to a mathematical analysis based on several large cohort longitudinal studies. Based on a multistate model for the Alzheimer's disease ... […]
Alzheimer’s disease is about to become a crisis. Here’s how California could lead
on May 22, 2018 at 12:00 pm
Despite the devastating toll of Alzheimer’s disease on patients and families, and the potential for its costs to bankrupt the medical system, research into AD has been stymied. The last time a drug was specifically approved for AD was in 2003. According ... […]
New tool predicts the lifetime risk of Alzheimer’s
on May 22, 2018 at 6:59 am
A new study funded by the National Institutes of Health has shown that the lifetime risk of developing Alzheimer’s disease significantly varies depending on age, gender and the presence of any signs or symptoms of dementia. The study authors say this is ... […]
Model estimates lifetime risk of Alzheimer's dementia using biomarkers
on May 22, 2018 at 5:52 am
Lifetime risks of developing Alzheimer's disease dementia vary considerably by age, gender and whether any signs or symptoms of dementia are present, according to a new study. According to the authors, these are the first lifetime risk estimates for ... […]
Study predicts most people with earliest Alzheimer’s signs won’t develop dementia associated with the disease
on May 21, 2018 at 9:18 pm
According to a new UCLA study, most people with preclinical signs of Alzheimer’s will not develop the full-scale disease. During the past decade, researchers have identified new ways to detect the earliest biological signs of Alzheimer’s disease. […]
via Bing News